Eventide Asset Management, LLC Incyte Corp Transaction History

Eventide Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $6.34 Million - $7.8 Million	121,508 New	121,508 $7.63 Million
Q4 2018 Feb 14, 2019	SELL	$58.5 - $69.94 $6.73 Million - $8.04 Million	-115,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $5.11 Million - $7.05 Million	84,000 Added 270.97%	115,000 $7.71 Million
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $332,240 - $403,920	4,000 Added 14.81%	31,000 $2.58 Million
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $1.22 Million - $1.52 Million	-13,000 Reduced 32.5%	27,000 $2.56 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $4.37 Million - $5.53 Million	40,000	40,000 $4.67 Million

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.